Clinical Trial Update: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease [Phase 3]

View source ↗

Summary

This entry covers a Phase 3 long-term extension study of mirikizumab in Crohn's disease, with results posted in December 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Mirikizumab (mirikizumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Crohn's Disease | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-12-15